In a filing, Y-Mabs Therapeutics Inc revealed its CHIEF BUSINESS OFFICER Gad Thomas unloaded Company’s shares for reported $0.88 million on Sep 13 ’24. In the deal valued at $13.47 per share,65,000 shares were sold. As a result of this transaction, Gad Thomas now holds 97,681 shares worth roughly $0.59 million.
Then, Gad Thomas sold 30,000 shares, generating $389,100 in total proceeds. Upon selling the shares at $12.97, the CHIEF BUSINESS OFFICER now owns 67,681 shares.
Before that, Thomas Gad bought 100,000 shares. Y-Mabs Therapeutics Inc shares valued at $1,374,000 were divested by the Officer at a price of $13.74 per share.
Oppenheimer initiated its Y-Mabs Therapeutics Inc [YMAB] rating to an Outperform in a research note published on November 18, 2024; the price target was $23. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid August with a ‘”an Overweight”‘ rating. Truist began covering YMAB with “Buy” recommendation on June 28, 2024. Wedbush revised its rating on May 10, 2023. It rated YMAB as “an Outperform” which previously was an “a Neutral”.
Price Performance Review of YMAB
On Tuesday, Y-Mabs Therapeutics Inc [NASDAQ:YMAB] saw its stock jump 3.45% to $6.00. Over the last five days, the stock has lost -1.48%. Y-Mabs Therapeutics Inc shares have fallen nearly -23.37% since the year began. Nevertheless, the stocks have fallen -55.19% over the past one year. While a 52-week high of $20.90 was reached on 01/02/25, a 52-week low of $5.71 was recorded on 02/03/25. SMA at 50 days reached $8.34, while 200 days put it at $11.98.
Levels Of Support And Resistance For YMAB Stock
The 24-hour chart illustrates a support level at 5.81, which if violated will result in even more drops to 5.62. On the upside, there is a resistance level at 6.13. A further resistance level may holdings at 6.26. The Relative Strength Index (RSI) on the 14-day chart is 27.05, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.55%. Stochastics %K at 12.48% indicates the stock is a buying.
How much short interest is there in Y-Mabs Therapeutics Inc?
A steep rise in short interest was recorded in Y-Mabs Therapeutics Inc stocks on 2025-01-15, growing by 0.12 million shares to a total of 3.74 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 3.62 million shares. There was a rise of 3.21%, which implies that there is a positive sentiment for the stock.
